| COVID-19 Vaccine |
1 |
1 |
| Vaccines |
0 |
0.98 |
| Immunization |
0 |
0.64 |
| Platelet Count |
0 |
0.61 |
| Thromboembolism |
0 |
0.53 |
| Patient Safety |
0 |
0.5 |
| COVID-19 |
0 |
0.97 |
| Cerebral Venous Thrombosis |
0 |
0.99 |
| Thrombosis |
0 |
0.44 |
| Biologic Therapy |
0 |
0.42 |
| Cerebrovascular Accident |
0 |
0.31 |
| Thrombocytopenia |
0 |
0.31 |
| Hospital |
0 |
0.2 |
| Otolaryngology |
0 |
0.19 |
| Cerebral Hemorrhage |
0 |
0.14 |
| Adenovirus |
0 |
0.1 |
| Adverse Effects |
0 |
0.1 |
| Geriatrics |
0 |
0.1 |
| Hemorrhage |
0 |
0.1 |
| Weakness |
0 |
0.1 |
| Intravenous Immunoglobulin (IVIG) |
0 |
0.09 |
| CT Scan |
0 |
0.08 |
| Traumatic Brain Injury |
0 |
0.08 |
| Headache |
0 |
0.06 |
| Anticoagulation Therapy |
0 |
0.05 |
| Board Certification |
0 |
0.05 |
| Brachial |
0 |
0.05 |
| Coma |
0 |
0.05 |
| Concerns of Elderly |
0 |
0.05 |
| Dorsum |
0 |
0.05 |
| Enzyme-Linked Immunosorbent Assay (ELISA) |
0 |
0.05 |
| Genetics |
0 |
0.05 |
| Grant |
0 |
0.05 |
| Immunoglobulin A (IgA) |
0 |
0.05 |
| Immunomodulator |
0 |
0.05 |
| Intravenous |
0 |
0.05 |
| Pandemic |
0 |
0.05 |
| Prognosis |
0 |
0.05 |
| Scan |
0 |
0.05 |
| Seizure |
0 |
0.05 |
| Severe Acute Respiratory Syndrome |
0 |
0.05 |
| Sinus |
0 |
0.05 |
| Stress |
0 |
0.05 |
| Acute Respiratory Distress Syndrome |
0 |
0.03 |
| Genomic Medicine |
0 |
0.03 |